142 Sansome Street
Second Floor
San Francisco, CA 94104
United States
415 432 9270
https://www.89bio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 70
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Rohan Palekar | CEO & Director | 1.06M | N/A | 1966 |
Mr. Quoc Le-Nguyen | Chief Technical Operations Officer & Head of Quality | 702.87k | N/A | 1968 |
Dr. Harry Mansbach M.D. | Chief Medical Officer | 732.87k | N/A | 1965 |
Mr. Ryan Stephen Martins | Chief Financial Officer | N/A | N/A | 1979 |
Mr. Shiva K. Natarajan CPA | Senior Vice President of Finance & Principal Accounting Officer | N/A | N/A | 1966 |
Ms. Annie J. Chang M.B.A. | VP of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Ms. Amanda Kurihara | Vice President of People & Culture | N/A | N/A | N/A |
Ms. Yun Bai Ph.D. | VP and Head of Chemistry, Manufacturing & Controls ( CMC ) | N/A | N/A | N/A |
Ms. Melissa Abel | Senior Vice President of Commercial Strategy | N/A | N/A | N/A |
Mr. Paul Shin | Senior Vice President of R&D Operations | N/A | N/A | N/A |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
89bio, Inc.’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 9; Compensation: 8.